Back to results
US 2026/0091050 A1Published application
Advantageous anti-hcv combination therapy
AssigneeAtea Pharmaceuticals, Inc.
InventorsJean-Pierre Sommadossi, Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou
Life of this patent
Estimating the term…
Abstract
A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:
Claims20
A method of treating HCV in a non-cirrhotic human in need thereof, comprising administering an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof,
- in a dosage form in combination with an effective amount of Compound 2, or a pharmaceutically acceptable salt thereof,
- in a dosage form.
Dependencies are inferred from the claim text.